Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Uncovers Prostate-Specific Proteins

NEW YORK, Feb. 14 - Compugen researchers have discovered two previously unknown prostate-specific proteins, the company said on Wednesday.


The proteins were first predicted by Compugen's computational biology platform, then verified through molecular biology techniques in the corporate labs.


The proteins are encoded by alternative mRNA splice variants of KlK3 and KLK2, genes that produce prostate specific antigen and human kallikrein 2 (hK2). Both PSA and hK2 are secreted in the human prostate and have been used as biomarkers for prostate cancer.


The newly discovered splice variant products are apparently unrelated to other proteins in the kallikrein family, but their expression, regulation, and secretion is similar to PSA. That finding suggests that these new proteins may prove to be useful in understanding the biology of prostate cancer, and suggest new drug targets or diagnostic markers.


The finding is published in The Journal of Biological Chemistry.


The LEADS bioinformatics platform incorporates genomics and proteomics tools and information from public and private databases to generate predictions of genes, mRNA transcripts, splice variants, and proteins.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.